Scholarlink

<p>Hypomethylating agents (HMA) alone or in combination with venetoclax (VEN) are a mainstay for disease control in elderly acute myeloid leukemia (AML). We evaluated the non-inferiority of HMA monotherapy compared to HMA/VEN combination in 227 AML patients aged ≥ 75&#xa0;years receiving HMA or HMA/VEN combination. No difference in overall survival (OS) was observed between the two groups, with HMA monotherapy demonstrating statistical non-inferiority. HMA-treated patients with favorable performance status had longer OS. The HMA/VEN group experienced higher mortality and worse QoL. HMA monotherapy offers comparable survival outcomes to HMA/VEN with reduced toxicity in elderly AML patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月11日

查看全文
  • Francesco Tarantini,
  • Corinne Contento,
  • Ernesto Vigna,
  • Vera Carluccio,
  • Giuseppina Greco,
  • Crescenza Pasciolla,
  • Lucia Ciuffreda,
  • Giovanni Rossi,
  • Marina Aurora Urbano,
  • Alessandro D’Ambrosio,
  • Lara Aprile,
  • Vito Pier Gagliardi,
  • Mario Delia,
  • Immacolata Attolico,
  • Paola Carluccio,
  • Vincenzo Federico,
  • Antonella Bruzzese,
  • Nicola Di Renzo,
  • Massimo Gentile,
  • Giuseppe Tarantini,
  • Anna Mele,
  • Attilio Guarini,
  • Lorella Maria Antonia Melillo,
  • Angelo Michele Carella,
  • Domenico Pastore,
  • Ferdinando Frigeri,
  • Alessandro Maggi,
  • Cosimo Cumbo,
  • Giorgina Specchia,
  • Pellegrino Musto,
  • Francesco Albano

摘要

Hypomethylating agents (HMA) alone or in combination with venetoclax (VEN) are a mainstay for disease control in elderly acute myeloid leukemia (AML). We evaluated the non-inferiority of HMA monotherapy compared to HMA/VEN combination in 227 AML patients aged ≥ 75 years receiving HMA or HMA/VEN combination. No difference in overall survival (OS) was observed between the two groups, with HMA monotherapy demonstrating statistical non-inferiority. HMA-treated patients with favorable performance status had longer OS. The HMA/VEN group experienced higher mortality and worse QoL. HMA monotherapy offers comparable survival outcomes to HMA/VEN with reduced toxicity in elderly AML patients.